US Corporate Distress Financial Stress SEC Filings — October 28, 2026

Nasdaq Hearings Panel delisting determination on October 23, 2026 with trading suspended since August 26, 2026; equity now OTC-only, which typically widens bid-ask spreads and reduces institutional access

$15M VXM01 put against BCM Europe AG reaffirmed and amended October 15, 2026 to allow settlement in convertible notes at roughly $2.00 to $5.00 per share, meaning settlement is effectively a dilutive equity-linked issuance rather than cash

Company declined a reverse stock split and says it will regain compliance through organic initiatives, a stance that is hard to reconcile with the already-completed delisting and implies limited near-term cure options

Company intends to seek continuation of its Shareholder Loyalty CVR Program, a retention-oriented instrument that may indicate management is attempting to preserve holder value through the OTC transition

Nasdaq deficiency notice under Rule 5450(a)(1) with 180 calendar days to April 21, 2027 to close at or above $1.00 for 10 consecutive business days; the listing is unaffected today, leaving a defined runway to restore compliance

Second 180-day compliance period under Rule 5810(c)(3)(A)(ii) is available, extending the potential cure horizon if the company meets the other listing requirements and gives notice of intent to cure

A transfer to the Nasdaq Capital Market is the fallback path, requiring a $5,000 fee and possibly a reverse split, which would be a concrete step toward reducing listing standards pressure

Nasdaq Hearings Panel denied continued listing on October 23, 2026, and the company has been suspended from Nasdaq since August 26, 2026, so the delisting is effectively final on the exchange side

The $15M VXM01 put can settle via convertible notes at $2.00 to $5.00 per share; at these levels, the potential share count increase against a sub-$1 stock is material and creates overhang

With Nasdaq access gone and a financing put priced in convertibles, the company's access to capital appears constrained, raising questions about its ability to fund operations without further dilution

The company promised a further update by November 6, 2026 on its options, and the unresolved status of its options (evaluating alternatives while remaining SEC-reporting) leaves investors without a clear path or timeline

OTC trading after exchange delisting generally means reduced liquidity and wider spreads, which can impair holders' ability to exit positions and increases execution cost

Share price has closed below $1.00 for 30 consecutive business days, and the notice warns that failure to cure can trigger staff review of a transfer and ultimately a delisting determination

Any delisting determination could be appealed to a Nasdaq Hearings Panel, but OSR's experience shows the Panel can deny continued listing, so the appeal route is not a reliable backstop

A rebound to a close at or above $1.00 for 10 consecutive business days before April 21, 2027 would fully resolve the deficiency, potentially re-rating the stock as overhang is removed

Eligibility for a second 180-day compliance period extends the cure timeline beyond April 2027, reducing forced-selling pressure from index or institutional mandates that exclude sub-$1 names

The fixed conversion range of $2.00 to $5.00 per share sits well above the current sub-$1 trading level, so the settlement mechanism is structurally unfavorable to the counterparty if the stock recovers, a feature worth tracking in the November 6 update

The November 6, 2026 update on strategic options is a dated event; any credible transaction, financing, or strategic outcome disclosed there could move a stock that is already in a repricing phase

If the Shareholder Loyalty CVR Program is continued, it may offer contingent value to remaining holders, providing a defined payoff structure in a deeply distressed equity

With 180 days to cure and the listing intact, Milestone sits at an earlier stage of the distress curve than OSR, offering a comparatively more time-bounded and lower-urgency situation for investors focused on recovery plays

Both filings reflect the same mechanism, sub-$1 equity pricing triggering Nasdaq Rule 5450(a)(1) or 5550(a)(2) compliance clocks, with outcomes diverging by stage: one company has been delisted and the other has 180 days, showing that timing within the compliance process determines the investor outcome [Implication: monitor other biotech and small-cap names showing persistent sub-$1 closes for similar notices]

OSR's use of a convertible note settlement priced at $2.00 to $5.00 per share for a $15M put illustrates how distressed issuers convert contractual obligations into dilutive instruments rather than cash, a pattern that tends to pressure existing holders [Implication: expect dilution-linked settlements to be a recurring feature of this stream]

OSR declined a reverse split in favor of organic remediation, while Milestone's notice explicitly flags a possible reverse split as a fallback, highlighting divergent management approaches to the same exchange rule [Implication: a reverse split decision is a useful signal of management conviction in organic recovery]

OSR's status as an SEC-reporting company trading OTC after Nasdaq delisting shows the typical post-exchange state for distressed names that remain filers, a useful reference for assessing liquidity and disclosure quality after delisting [Implication: track OTC-migrated names for disclosure consistency and liquidity deterioration]

Company promised a further update by November 6, 2026 on its evaluation of options following the delisting determination; watch for any financing, sale, restructuring, or wind-down language

Monitor whether BCM Europe AG elects convertible note settlement and the terms of any resulting issuance against the $2.00 to $5.00 conversion range

Watch for the company's request for continuation of the CVR program and any terms that define contingent value for remaining holders

April 21, 2027 is the 180-day deadline to close at or above $1.00 for at least 10 consecutive business days; track daily closes against the $1.00 threshold

Watch for any notice of intent to cure or a request for the additional 180-day period under Rule 5810(c)(3)(A)(ii) as the first deadline approaches

Monitor for any board action on a reverse split or an application to transfer to the Nasdaq Capital Market, which would signal a shift from organic cure to structural remediation